Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Zachary Conrad Hartman"'
Autor:
Xiao Yang, Michael A Morse, Takuya Osada, Amy Hobeika, Herbert Kim Lyerly, Zachary Conrad Hartman, Hiroshi Nagata, Kensuke Kaneko, Chaitanya R Acharya, Philip F Hughes, Timothy A J Haystead
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 9 (2022)
Background We previously demonstrated potent antitumor activity against human breast cancer xenografts using photodynamic therapy (PDT) targeting a novel tumor-specific photosensitizer (HS201), which binds heat shock protein 90 (HS201-PDT). However,
Externí odkaz:
https://doaj.org/article/565e94da5b9048f6b975c2f576e21cce
Autor:
Tao Wang, Michael A Morse, Takuya Osada, Herbert Kim Lyerly, Junping Wei, Xiao-Yi Yang, Gangjun Lei, Zachary Conrad Hartman, Pankaj Agarwal, Li-Chung Tsao, Chaitanya R Acharya, Bin-Jin Hwang, Timothy Trotter
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 3 (2022)
Background The majority of colorectal carcinomas (CRCs) are insensitive to programmed death protein-1/programmed death-ligand 1 (anti-PD-1/PD-L1) immune checkpoint inhibitor (ICI) antibodies. While there are many causes for ICI insensitivity, recent
Externí odkaz:
https://doaj.org/article/7313de08ca68445aa4436a03e31eed63
Autor:
Tao Wang, Herbert Kim Lyerly, Alan Chen Chen, Renhuan Xu, Junping Wei, Xiao-Yi Yang, Cong-Xiao Liu, Gangjun Lei, Teri Heiland, Zachary Conrad Hartman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Background The advent of immune checkpoint blockade antibodies has demonstrated that effective mobilization of T cell responses can cause tumor regression of metastatic cancers, although these responses are heterogeneous and restricted to certain his
Externí odkaz:
https://doaj.org/article/6cdeb5056cb243e1839fdc148a8a38ff
Autor:
Kensuke Kaneko, Chaitanya R Acharya, Hiroshi Nagata, Xiao Yang, Zachary Conrad Hartman, Amy Hobeika, Philip F Hughes, Timothy A J Haystead, Michael A Morse, Herbert Kim Lyerly, Takuya Osada
Publikováno v:
Journal for immunotherapy of cancer. 10(9)
BackgroundWe previously demonstrated potent antitumor activity against human breast cancer xenografts using photodynamic therapy (PDT) targeting a novel tumor-specific photosensitizer (HS201), which binds heat shock protein 90 (HS201-PDT). However, i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a241fc1accf178ca193ba99ec985584
https://pubmed.ncbi.nlm.nih.gov/36171008
https://pubmed.ncbi.nlm.nih.gov/36171008
Autor:
Li-Chung Tsao, Zachary Conrad Hartman
Publikováno v:
Cancer Research. 83:2944-2944
Background: T-DXd is a new antibody-drug conjugate targeting HER2 that has demonstrated superior clinical efficacy over previous HER2-targeting agent Trastuzumab emtansine (T-DM1) in patients with advanced-stage HER2+ breast cancer (BC). T-Dxd consis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c52c6e462f16e05818161a92b64f48dd
https://doi.org/10.1158/1538-7445.am2023-2944
https://doi.org/10.1158/1538-7445.am2023-2944
Autor:
Bin-Jin Hwang, Li-Chung Tsao, Chaitanya R Acharya, Timothy Trotter, Pankaj Agarwal, Junping Wei, Tao Wang, Xiao-Yi Yang, Gangjun Lei, Takuya Osada, Herbert Kim Lyerly, Michael A Morse, Zachary Conrad Hartman
Publikováno v:
Journal for ImmunoTherapy of Cancer. 10:e003721
BackgroundThe majority of colorectal carcinomas (CRCs) are insensitive to programmed death protein-1/programmed death-ligand 1 (anti-PD-1/PD-L1) immune checkpoint inhibitor (ICI) antibodies. While there are many causes for ICI insensitivity, recent s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1dbf50bbad0634166b3210ecd3bc5906
https://doi.org/10.1136/jitc-2021-003721
https://doi.org/10.1136/jitc-2021-003721